TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. ages between 18 and 65;~2. BD current acute mixed episode;~3. total capacity to understand and respond to self-applied instruments;~4. the presence of symptoms in the last 30 days;~5. abstinence for at least 30 days for drug addicts.~Exclusion Criteria:~1. presence of Organic Brain Syndrome (OBS);~2. pregnancy or lactation;~3. criteria for psychiatric hospitalization. -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lithium Carbonate (Type: EXPERIMENTAL): Group Started: Lithium Carbonate (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Lithium (LSL 0.6-0.8). Non responsive patients: 2nd step.~Second step: Monotherapy with lithium (LSL 1.0-1.2). Non responsive patients: 3rd step.~Third step: Lithium + Sertraline (50mg-200mg). Non responsive patients: 4th step.~Fourth step: Lithium + Nortriptyline 100mg. Non responsive patients: 5th step.~Fifth step: Lithium + Nortriptyline 100mg + Sertraline (100mg-200mg). Non responsive patients: 6th step~Sixth step: Lithium + Nortriptyline 100mg + Sertraline 200mg + Risperidone (1mg-6mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects and/or female subjects of non-childbearing potential between the ages of 18 and 55 years~* Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study~* Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures~Exclusion Criteria:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease~* Any condition possibly affecting drug absorption~* Male subjects who are unwilling or unable to use a highly effective method of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Palbociclib given to healthy volunteers (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Depression in the Children of Depressed African American Mothers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Mothers:~Inclusion Criteria:~* African American~* Primary current or past-year diagnostic and statistical manual (DSM-IV) diagnosis of Major Depressive Disorder, Dysthymic Disorder, or Depressive Disorder not otherwise specified~* Parent or guardian and primary caregiver of a child 8 to 14 years old~* Resided at least part time for the past year with the targeted child~* May be receiving psychopharmacological treatment, psychosocial services, or both~Exclusion Criteria:~* Current or lifetime history of schizophrenia~* Current or lifetime history of bipolar disorder~* Current or past-year diagnosis of alcohol or drug dependency~* Serious medical disorder, neurological disorder, condition, or chronic pain that prevents participation~* Documented mental retardation~* Current suicide risk sufficient to preclude outpatient treatment~Children:~Inclusion Criteria:~* Have an African American mother with a depressive disorder~* 8 to 14 years old~* Reside at least part time with mother~Exclusion Criteria:~* Currently in treatment for depression or an anxiety disorder~* Presence of a medical or psychiatric condition contraindicating study intervention, such as mental retardation, suicidality, or pervasive developmental disorder

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Adapted PIP (Type: EXPERIMENTAL): Participants (both mother and children) participated in an adapted cognitive family prevention program for the families of children with a depressed African American mother.~The intervention was the Prevention Intervention Project.
- Lecture (Type: ACTIVE_COMPARATOR): Mothers received psychoeducation about depression.~The intervention was psychoeducation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Integrated Alcohol Disorder and PTSD Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans who were victims of psychological trauma that occurred in childhood or adulthood.~* At least one month post-trauma.~* Age 18 or older.~* Meeting diagnostic criteria for current alcohol dependence and PTSD.~* Literate in English.~* Intend to stay in San Diego during study participation.~* Willing to attend psychotherapy and measurement sessions.~* Willing to stay cut down alcohol use significantly during treatment.~Exclusion Criteria:~* Moderate or severe cognitive impairment on the Brief Neuropsychological (NP) Assessment Battery as this may interfere with ability to benefit from treatment.~* Acutely suicidal individuals will be referred for more appropriate treatment.~* Histories of psychosis or mania independent of substance use will be excluded because the presence of these disorders can impede therapy progress.~* Individuals who use intravenous drugs will be excluded.~* Participants who do not have adequate memory of the trauma will be excluded because such memory is necessary for exposure therapy.~* Only Veterans residing within 50 miles of the site will be included.~* Those with life threatening or unstable medical illness, documented neurological disorder, or inability to read will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Integrated Prolonged Exposure Therapy (Type: EXPERIMENTAL): Integrated Prolonged exposure Psychotherapy (I-PE; PE integrated with elements of Integrated Cognitive Behavioral Therapy for alcohol use disorder)
- Arm 2: Seeking Safety (Type: ACTIVE_COMPARATOR): Seeking Safety

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60 adult Chinese subjects aged 18-60 without known platelet disorder, thrombocytopenia, history of taking drugs that may affect platelet function including herbal preparations.~Exclusion Criteria:~1. Any known platelet or coagulation disorder~2. Expected surgical operation or dental treatment within one week of scheduled drug intake.~3. Known peptic ulcer disease~4. Obesity (BMI \>=30)~5. Pregnant or lactating women.~6. Known chronic liver or renal disease.~7. Coronary artery, carotid artery or peripheral artery disease~8. Recent history of taking antiplatelet drugs, anticoagulants or herbal preparations.~9. Smoker or alcohol user~10. Mentally incapable of providing informed consent~11. Students or junior staff members who had direct working relationship with the PI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Placebo group (Type: PLACEBO_COMPARATOR): Subjects will be given placebo daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15 microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
- Aspirin group (Type: ACTIVE_COMPARATOR): Subjects will be given aspirin 100mg daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Apidra to Regular Insulin in Hospitalized Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be admitted to non-critical care units with expected length of stay of at least three days.~* Subjects must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.~* Subjects may be of either sex. Female subjects of child-bearing potential must be non-lactating and have a negative pregnancy test before starting the study.~* Subjects must be diagnosed with T2DM or develop hyperglycemia (BG \>180 mg/dl) during hospitalization.~Exclusion Criteria:~* Subjects must not be admitted for 'observation' or for expected length of stay of less than three days.~* Subjects must not have Type 1 Diabetes.~* Subjects must not be using rapid acting insulin analogues.~* Subjects must not be receiving nutrition via tube feedings.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apidra (Type: ACTIVE_COMPARATOR): Direct 1:1 comparison of Apidra and Regular insulin.
- Regular (Type: ACTIVE_COMPARATOR): Direct 1:1 comparison of Apidra and Regular insulin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Increased Ketorolac Administration After Cesarean Section and Its Effect on Opioid Use: a Randomized Control Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women presenting for care at Tufts Medical Center as an outpatient in obstetrics clinic or on Labor and Delivery.~* The subject must have had a cesarean section for any indication at Tufts Medical Center to be randomized to the study~* The subject is willing to have a phone call follow up conversation 2 weeks after their surgery.~Exclusion Criteria:~* Patients with allergy to ketorolac, NSAIDS or aspirin~* Patients with peptic ulcer disease, preexisting kidney or liver disease.~* Duramorph is not used as the anesthetic for the spinal/epidural during the cesarean section.~* Patient is hemodynamically unstable due to hemorrhage.~* Patient requires therapeutic anticoagulation in the post-operative period~* Patients with peripartum cardiomyopathy~* Provider decision to exclude patient.~* Patient diagnosis of chronic hypertension, gestational hypertension, preeclampsia, HELLP syndrome, or eclampsia~* A study subject may participate in another research study while participating in this research study.

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard Protocol (Type: NO_INTERVENTION): Subjects randomized to the standard group will receive the standard postoperative pain protocol that is currently used at Tufts Medical Center. It includes two doses of IV Ketorolac every 6 hours as needed for postoperative pain. Ibuprofen would be ordered 6 hours following the last dose after the last study drug.
- Ketorolac Protocol (Type: EXPERIMENTAL): Subjects randomized to the Ketorolac protocol will receive the study postoperative pain protocol. This includes 6 doses of IV Ketorolac, scheduled every 6 hours. The first dose is administered in the operating room or post-operative care unit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Catatonia in Nodding Syndrome and Lorazepam Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Children and adolescents with Nodding Syndrome as defined by the consensus definition agreed upon in the international Nodding Syndrome research meeting held in Kampala, Uganda July 2012.~2. Presence of two or more catatonic items on the Kampala Catatonia Panel.~3. Written informed consent from caregiver.~Exclusion Criteria:~1. Children and adolescents with Nodding Syndrome who had a history of having used a benzodiazepine drug in the past 48 hours prior to intervention.~2. Children and adolescents with Nodding Syndrome who had a concurrent acute illness (e.g febrile illness, pneumonia) at time of assessment.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Lorazepam (Type: EXPERIMENTAL): Children with confirmed Nodding syndrome that had 2 or more of the symptoms on the 10-item Kampala Catatonia Panel (KCP) scale were recruited to undergo the catatonia test using oral Lorazepam EG® (n.v. Eurogenerics s.a. Brussels, Belgium) using the 1 mg formulation tablets. The amount of Lorazepam (LZP) drug given orally was based on the weight of the child. The lower dose (0.5 mg) was used as starting dose for patients with \<30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with \>30 kg body weight.~A positive response to a catatonia test consisted of a reduction in catatonic symptoms, 60 minutes later, by at least 50% assessed by the KCP (using all 10 items). If no response to the initial dose of LZP, was observed after one hour, a second administration of the same medication at double the dose was given. Catatonia was again assessed at 60 minutes thereafter. If no response was observed, the test was considered negative.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria~* Levodopa-responsive with severe motor fluctuations~* Recognizable off and on state (motor fluctuations) confirmed by diary~Exclusion Criteria:~* Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism~* Undergone surgery for the treatment of PD~* Contraindications to levodopa (such as narrow angle glaucoma)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levodopa-Carbidopa Intestinal Gel (LCIG) (Type: EXPERIMENTAL): All participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Breakthrough Dyspnea Fentanyl Study in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of cancer~2. Breakthrough dyspnea, defined in this study as dyspnea on exertion with an average intensity level \>=3/10 on the numeric rating scale~3. Outpatient or inpatient at MD Anderson Cancer Center seen by the Supportive Care or Rehabilitation Service~4. Able to communicate in English or Spanish~5. Ambulatory and able to walk with or without walking aid~6. On strong opioids with morphine equivalent daily dose of 30-580 mg, with stable (i.e. +/- 30%) regular dose over the last 24 hours~7. Karnofsky performance status \>=50%~8. Age 18 or older~Exclusion Criteria:~1. Dyspnea at rest \>=7/10 at the time of enrollment~2. Supplemental oxygen requirement \>6 L per minute~3. Delirium (i.e. Memorial delirium rating scale \>13)~4. History of unstable angina or myocardial infarction 1 month prior to study enrollment~5. Resting heart rate \>120 at the time of study enrollment~6. Systolic pressure \>180 mmHg or diastolic pressure \>100 mmHg at the time of study enrollment~7. History of active substance abuse within the past 12 months~8. History of allergy to fentanyl~9. Unwilling to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fentanyl (Type: EXPERIMENTAL): Fentanyl subcutaneously (SQ) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before walk test, and 6 minute walk test (6MWT) at baseline and 15 minutes after Fentanyl. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
- Placebo (Type: ACTIVE_COMPARATOR): Normal saline 0.9% preservative free SQ 15 minutes before walk test, and 6 minute walk test at baseline and 15 minutes after Placebo. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women, aged ≥ 55 to ≤ 90.~* Received oral bisphosphonate therapy for at least 3 years immediately prior to screening~* BMD T-score ≤ -2.50 at the lumbar spine, total hip or femoral neck~* History of nonvertebral fracture after age 50, or vertebral fracture.~Exclusion Criteria:~* Use of other agents affecting bone metabolism including Strontium ranelate, fluoride (for osteoporosis), odanacatib (MK-0822) or any other cathepsin K inhibitor, IV bisphosphonates, denosumab, teriparatide (TPTD) or any parathyroid hormone (PTH) analogs, Systemic oral or transdermal estrogen, selective estrogen receptor modulators (SERMs), activated vitamin D3, vitamin K2, calcitonin, tibolone, cinacalcet, systemic glucocorticosteroids:~* History of metabolic or bone disease (except osteoporosis) that may interfere with the interpretation of study results, such as sclerosteosis, Paget's disease, rheumatoid arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome.~* Vitamin D insufficiency, defined as 25 (OH) vitamin D levels \< 20 ng/mL, as determined by the central laboratory.~* Current hyper- or hypocalcemia~* Current, uncontrolled hyper- or hypothyroidism

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Romosozumab (Type: EXPERIMENTAL): Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
- Teriparatide (Type: ACTIVE_COMPARATOR): Participants received 20 μg/day teriparatide administered by subcutaneous injection for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete